Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible Patients with Muscle Invasive Bladder Cancer By Ogkologos - November 18, 2024 674 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma MOST POPULAR The Barriers to Care Faced by LGBTQ People With Cancer: An... January 21, 2021 Plans for NCI’s Fiscal Year 2019 Budget December 18, 2018 Sotorasib in Combination with Panitumumab Results in Longer PFS in Patients... December 6, 2023 Oncotype DX Breast Cancer Test May Be Less Accurate for Black... February 26, 2021 Load more HOT NEWS “No Person With Cancer or Survivor Should Ever Feel Alone”: A... A “Living Medicine:” Engineered E. coli Shrink Tumors in Mice Antioxidant Use Before And During Chemo Increases Risk Of Relapse, Death... Study Finds Shortcomings in Monitoring Caregivers’ Emotional Health
